MoneyWorks4Me

Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine

06 Oct 2021 Evaluate

Cadila Healthcare has received permission from the Drug Controller General of India (DCGI) for conducting phase III trials for its two-dose COVID-19 vaccine ZyCoV-D. The company has already received the emergency use authorization (EUA) from the DCGI for ZyCoV-D to be administered in three doses on August 20, 2021.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..